Enlivex Therapeutics to present clinical data of Allocetra in osteoarthritis

Enlivex Therapeutics (ENLV) announced that it will present a poster at the European Alliance of Associations for Rheumatology, EULAR, European Congress of Rheumatology, taking place June 11-14, 2025, in Barcelona, Spain. The Company’s presentation will feature data from the ongoing clinical study evaluating Allocetra, Enlivex’s proprietary, off-the-shelf macrophage reprogramming cell therapy, in patients with knee osteoarthritis. Allocetra is designed to reprogram macrophages into a homeostatic state, thereby promoting immune balance and resolution of chronic inflammation. Allocetra has demonstrated favorable safety and promising efficacy signals in Phase I/II studies in patients with moderate and end-stage knee osteoarthritis, including substantial and durable pain reduction, improved joint function, and avoidance of knee replacement surgery. The Company recently announced that it had completed the enrollment of all patients in the Phase II stage of its randomized, controlled, blinded Phase I/II trial of Allocetra in patients with moderate to severe knee osteoarthritis. The Company expects a topline data readout from the Phase II stage by August 2025.